All Alnylam articles
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessBreaking the silence of RNA interference drugs
A wave of treatments is set to follow the first approval of an RNAi therapy
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
BusinessSilence Therapeutics and Alnylam in patent dispute
Suit alleges competitors need to license Silence patents relating to their drug cantidates
-
Business
Alnylam accuses Dicerna of stealing trade secrets
Firm claims rights to GalNAc conjugated siRNA technology acquired from Merck & Co